본문 바로가기
KERD
논문KCI 등재

Role of the renin-angiotensin system in hepatic fibrosis and portal hypertension

Moon Young Kim|Seong Hee Kang|Soon Koo Baik|엄영우|Kwang Yong Shim
대한내과학회 (The Korean Association Of Internal Medicine)|2018.05|The Korean Journal of Internal Medicine|제33권 제3호|pp. 453-461|DOI https://doi.org/10.3904/kjim.2017.317

2

조회

0

다운로드

2

인용

0

참고문헌

키워드

HypertensionportalRenin-angiotensin systemHepatic fibrosisReceptorsAngiotensinsangiotensin
주제분류내과학

초록

The renin-angiotensin system (RAS) is an important regulator of cirrhosis and portal hypertension. As hepatic fibrosis progresses, levels of the RAS components angiotensin (Ang) II, Ang-(1–7), angiotensin-converting enzyme (ACE), and Ang II type 1 receptor (AT1R) are increased. The primary effector Ang II regulates vasoconstriction, sodium homoeostasis, fibrosis, cell proliferation, and inflammation in various diseases, including liver cirrhosis, through the ACE/Ang II/AT1R axis in the classical RAS. The ACE2/Ang-(1–7)/Mas receptor and ACE2/Ang-(1–9)/ AT2R axes make up the alternative RAS and promote vasodilation, antigrowth, proapoptotic, and anti-inflammatory effects; thus, countering the effects of the classical RAS axis to reduce hepatic fibrogenesis and portal hypertension. Patients with portal hypertension have been treated with RAS antagonists such as ACE inhibitors, Ang receptor blockers, and aldosterone antagonists, with very promising hemodynamic results. In this review, we examine the RAS, its roles in hepatic fibrosis and portal hypertension, and current therapeutic approaches based on the use of RAS antagonists in patients with portal hypertension.

Abstract

The renin-angiotensin system (RAS) is an important regulator of cirrhosis and portal hypertension. As hepatic fibrosis progresses, levels of the RAS components angiotensin (Ang) II, Ang-(1–7), angiotensin-converting enzyme (ACE), and Ang II type 1 receptor (AT1R) are increased. The primary effector Ang II regulates vasoconstriction, sodium homoeostasis, fibrosis, cell proliferation, and inflammation in various diseases, including liver cirrhosis, through the ACE/Ang II/AT1R axis in the classical RAS. The ACE2/Ang-(1–7)/Mas receptor and ACE2/Ang-(1–9)/ AT2R axes make up the alternative RAS and promote vasodilation, antigrowth, proapoptotic, and anti-inflammatory effects; thus, countering the effects of the classical RAS axis to reduce hepatic fibrogenesis and portal hypertension. Patients with portal hypertension have been treated with RAS antagonists such as ACE inhibitors, Ang receptor blockers, and aldosterone antagonists, with very promising hemodynamic results. In this review, we examine the RAS, its roles in hepatic fibrosis and portal hypertension, and current therapeutic approaches based on the use of RAS antagonists in patients with portal hypertension.

참고문헌 (96)

  1. Lavoie JL, "Minireview: overview of the renin-angiotensin system: an endocrine and paracrine system", Endocrinology, 144, pp.2179~2183 (2003)[DOI]
  2. Bataller R, "Liver fibrosis", J Clin Invest, 115, pp.209~218 (2005)[DOI]
  3. Tox U, "Impact of inhibitors of the renin-angiotensin-aldosterone system on liver fibrosis and portal hypertension", Curr Med Chem, 13, pp.3649~3661 (2006)[DOI]
  4. Kang SH, "Novelties in the pathophysiology and management of portal hypertension: new treatments on the horizon", Hepatol Int, 12(Suppl 1), pp.112~121 (2018)[DOI]
  5. Paizis G, "Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver", Gastroenterology, 123, pp.1667~1676 (2002)[DOI]
  6. Bataller R, "Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II", Gastroenterology, 125, pp.117~125 (2003)[DOI]
  7. Sakata T, "Diagnostic significance of serum angiotensin-converting enzyme activity in biochemical tests with special reference of chronic liver diseases", Jpn J Med, 30, pp.402~407 (1991)[DOI]
  8. Paizis G, "Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2", Gut, 54, pp.1790~1796 (2005)[DOI]
  9. Herath CB, "Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1-7) levels in experimental biliary fibrosis", J Hepatol, 47, pp.387~395 (2007)[DOI]
  10. Rockey D, "The cellular pathogenesis of portal hypertension: stellate cell contractility, endothelin, and nitric oxide", Hepatology, 25, pp.2~5 (1997)[DOI]
  11. Kaneda K, "Endothelin-1-induced vasoconstriction causes a significant increase in portal pressure of rat liver: localized constrictive effect on the distal segment of preterminal portal venules as revealed by light and electron microscopy and serial reconstruction", Hepatology, 27, pp.735~747 (1998)[DOI]
  12. Bhathal PS, "Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators", J Hepatol, 1, pp.325~337 (1985)[DOI]
  13. Grace JA, "Update on new aspects of the renin-angiotensin system in liver disease: clinical implications and new therapeutic options", Clin Sci (Lond), 123, pp.225~239 (2012)[DOI]
  14. 김가은, "Transient elastography versus hepatic venous pressure gradient for diagnosing portal hypertension: a systematic review and meta-analysis", Clinical and Molecular Hepatology, 23(1), pp.34~41 (2017), 대한간학회[DOI]
  15. Dickstein K, "Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan", Lancet, 360, pp.752~760 (2002)[DOI]
  16. Kim G, "Renin-angiotensin system inhibitors and fibrosis in chronic liver disease: a systematic review", Hepatol Int, 10, pp.819~828 (2016)[DOI]
  17. Yoo Li Lim, "Clinical Implications of the Serum Apelin Level on Portal Hypertension and Prognosis of Liver Cirrhosis", Gut and Liver, 10(1), pp.109~116 (2016), 거트앤리버 소화기연관학회협의회
  18. 김가은, "Therapeutic Effects of Mesenchymal Stem Cells for Patients with Chronic Liver Diseases: Systematic Review and Meta-analysis", Journal of Korean Medical Science, 30(10), pp.1405~1415 (2015), 대한의학회
  19. Lubel JS, "Liver disease and the renin-angiotensin system: recent discoveries and clinical implications", J Gastroenterol Hepatol, 23, pp.1327~1338 (2008)[DOI]
  20. Suzuki Y, "Inflammation and angiotensin II", Int J Biochem Cell Biol, 35, pp.881~900 (2003)[DOI]
  21. Ruiz-Ortega M, "Proinflammatory actions of angiotensins", Curr Opin Nephrol Hypertens, 10, pp.321~329 (2001)[DOI]
  22. Mezzano SA, "Angiotensin II and renal fibrosis", Hypertension, 38(3), pp.635~638 (2001)[DOI]
  23. Marrero MB, "Direct stimulation of Jak", STAT pathway by the angiotensin II AT1 receptor, 1995, pp.375, 247~250
  24. Kagami S, "Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells", J Clin Invest, 93, pp.2431~2437 (1994)[DOI]
  25. Hunyady L, "Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II", Mol Endocrinol, 20, pp.953~970 (2006)[DOI]
  26. Mehta PK, "Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system", Am J Physiol Cell Physiol, 292, pp.C82~C97 (2007)[DOI]
  27. de Gasparo M, "International union of pharmacology. XXIII. The angiotensin II receptors", Pharmacol Rev, 52, pp.415~472 (2000)
  28. Dinh DT, "Angiotensin receptors: distribution, signalling and function", Clin Sci (Lond), 100, pp.481~492 (2001)[DOI]
  29. Griendling KK, "The angiotensin (AT1) receptor", Semin Nephrol, 13, pp.558~566 (1993)
  30. Schieffer B, "Importance of tyrosine phosphorylation in angiotensin II type 1 receptor signaling", Hypertension, 27(3), pp.476~480 (1996)[DOI]
  31. Nguyen G, "Pivotal role of the renin", prorenin receptor in angiotensin II production and cellular responses to renin, 2002, pp.109, 1417~1427
  32. Feldt S, "Prorenin and renin-induced extracellular signal-regulated kinase 1", 2 activation in monocytes is not blocked by aliskiren or the handle-region peptide, 2008, pp.51, 682~688
  33. Crackower MA, "Angiotensin-converting enzyme 2 is an essential regulator of heart function", Nature, 417, pp.822~828 (2002)[DOI]
  34. Donoghue M, "A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9", Circ Res, 87, pp.E1~E9 (2000)[DOI]
  35. Yoshiji H, "Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat", BMC Res Notes, 2, pp.70~ (2009)[DOI]
  36. Vickers C, "Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase", J Biol Chem, 277, pp.14838~14843 (2002)[DOI]
  37. Villela DC, "Alamandine: a new member of the angiotensin family", Curr Opin Nephrol Hypertens, 23, pp.130~134 (2014)[DOI]
  38. Santos RA, "Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas", Proc Natl Acad Sci U S A, 100, pp.8258~8263 (2003)[DOI]
  39. Lima CV, "Potentiation of the hypotensive effect of bradykinin by short-term infusion of angiotensin-(1-7) in normotensive and hypertensive rats", Hypertension, 30(3), pp.542~548 (1997)[DOI]
  40. Tallant EA, "Molecular mechanisms of inhibition of vascular growth by angiotensin-(1-7)", Hypertension, 42, pp.574~579 (2003)[DOI]
  41. Henrion D, "Physiological and pathophysiological functions of the AT(2) subtype receptor of angiotensin II: from large arteries to the microcirculation", Hypertension, 38, pp.1150~1157 (2001)[DOI]
  42. Touyz RM, "Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells", Pharmacol Rev, 52, pp.639~672 (2000)
  43. Tsochatzis EA, "Liver cirrhosis", Lancet, 383, pp.1749~1761 (2014)[DOI]
  44. 김가은, "Diagnostic Accuracy of Hepatic Vein Arrival Time Performed with Contrast-Enhanced Ultrasonography for Cirrhosis: A Systematic Review and Meta-Analysis", Gut and Liver, 11(1), pp.93~101 (2017), 거트앤리버 소화기연관학회협의회
  45. Bosch J, "Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension", J Hepatol, 53, pp.558~567 (2010)[DOI]
  46. 김문영, "간경변 및 문맥압 항진증에서 과역동 혈역학 변화", 대한소화기학회지, 54(3), pp.143~148 (2009), 대한소화기학회
  47. Lichtinghagen R, "Matrix metalloproteinase (MMP)-2, MMP-7, and tissue inhibitor of metalloproteinase-1 are closely related to the fibroproliferative process in the liver during chronic hepatitis C", J Hepatol, 34, pp.239~247 (2001)[DOI]
  48. 백순구, "간성상세포의 수축 및 성장에 대한 Angiotensin Ⅱ 수용체 길항제의 억제 효과", 대한소화기학회지, 42(2), pp.134~141 (2003), 대한소화기학회
  49. Bataller R, "Angiotensin II induces contraction and proliferation of human hepatic stellate cells", Gastroenterology, 118, pp.1149~1156 (2000)[DOI]
  50. Bataller R, "NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis", J Clin Invest, 112, pp.1383~1394 (2003)[DOI]
  51. Jang YO, "Effect of function-enhanced mesenchymal stem cells infected with decorin-expressing adenovirus on hepatic fibrosis", Stem Cells Transl Med, 5, pp.1247~1256 (2016)[DOI]
  52. Moreno-Alvarez P, "Angiotensin II increases mRNA levels of all TGF-beta isoforms in quiescent and activated rat hepatic stellate cells", Cell Biol Int, 34, pp.969~978 (2010)[DOI]
  53. Lubel JS, "Angiotensin-(1-7), an alternative metabolite of the renin-angiotensin system, is up-regulated in human liver disease and has antifibrotic activity in the bile-duct-ligated rat", Clin Sci (Lond), 117, pp.375~386 (2009)[DOI]
  54. Pereira RM, "The renin-angiotensin system in a rat model of hepatic fibrosis: evidence for a protective role of Angiotensin-(1-7)", J Hepatol, 46, pp.674~681 (2007)[DOI]
  55. Suk KT, "Transplantation with autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: phase 2 trial", Hepatology, 64, pp.2185~2197 (2016)[DOI]
  56. Burrell LM, "Myocardial infarction increases ACE2 expression in rat and humans", Eur Heart J, 26, pp.369~375 (2005)[DOI]
  57. Osterreicher CH, "Angiotensin-converting-enzyme 2 inhibits liver fibrosis in mice", Hepatology, 50, pp.929~938 (2009)
  58. Albornoz L, "Nitric oxide synthase activity in the splanchnic vasculature of patients with cirrhosis: relationship with hemodynamic disturbances", J Hepatol, 35, pp.452~456 (2001)[DOI]
  59. Sieber CC, "Role of nitric oxide in the in vitro splanchnic vascular hyporeactivity in ascitic cirrhotic rats", Gastroenterology, 104, pp.1750~1754 (1993)[DOI]
  60. 김가은, "Assessment for Risk of Bias in Systematic Reviews and Meta-Analyses in the Field of Hepatology", Gut and Liver, 9(6), pp.701~706 (2015), 거트앤리버 소화기연관학회협의회
  61. Tandon P, "Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis", J Hepatol, 53, pp.273~282 (2010)[DOI]
  62. 박동훈, "담관결찰 쥐에서 안지오텐신 길항제의 간섬유화 억제 효과", Clinical and Molecular Hepatology, 13(1), pp.61~69 (2007), 대한간학회
  63. Angus PW, "Role of endothelin in systemic and portal resistance in cirrhosis", Gut, 55, pp.1230~1232 (2006)[DOI]
  64. Kim G, "Relative adrenal insufficiency in patients with cirrhosis: a systematic review and meta-analysis", Dig Dis Sci, 62, pp.1067~1079 (2017)[DOI]
  65. Ferrario CM, "Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function", Am J Physiol Heart Circ Physiol, 289, pp.H2281~H2290 (2005)[DOI]
  66. Lebrec D, "Propranolol: a medical treatment for portal hypertension?", Lancet, 2, pp.180~182 (1980)
  67. Tripathi D, "Beta-blockers in portal hypertension: new developments and controversies", Liver Int, 34, pp.655~667 (2014)[DOI]
  68. Poynard T, "Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices: an analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco-Italian Multicenter Study Group", N Engl J Med, 324, pp.1532~1538 (1991)[DOI]
  69. Garcia-Tsao G, "Management of varices and variceal hemorrhage in cirrhosis", N Engl J Med, 362, pp.823~832 (2010)[DOI]
  70. Feu F, "Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis", Lancet, 346, pp.1056~1059 (1995)[DOI]
  71. Groszmann RJ, "Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis", N Engl J Med, 353, pp.2254~2261 (2005)[DOI]
  72. Garcia-Pagan JC, "Long-term haemodynamic effects of isosorbide 5-mononitrate in patients with cirrhosis and portal hypertension", J Hepatol, 11, pp.189~195 (1990)[DOI]
  73. Albillos A, "Hemodynamic effects of alpha-adrenergic blockade with prazosin in cirrhotic patients with portal hypertension", Hepatology, 20, pp.611~617 (1994)
  74. Esler M, "Increased sympathetic nervous activity and the effects of its inhibition with clonidine in alcoholic cirrhosis", Ann Intern Med, 116, pp.446~455 (1992)[DOI]
  75. Debernardi-Venon W, "AT1 receptor antagonist Candesartan in selected cirrhotic patients: effect on portal pressure and liver fibrosis markers", J Hepatol, 46, pp.1026~1033 (2007)
  76. Schneider AW, "Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis", Hepatology, 29, pp.334~339 (1999)[DOI]
  77. Baik SK, "Captopril reduces portal pressure effectively in portal hypertensive patients with low portal venous velocity", J Gastroenterol, 38, pp.1150~1154 (2003)[DOI]
  78. Kim MY, "Angiotensin receptor blockers are superior to angiotensin-converting enzyme inhibitors in the suppression of hepatic fibrosis in a bile duct-ligated rat model", J Gastroenterol, 43, pp.889~896 (2008)[DOI]
  79. Heim MH, "The angiotensin II receptor antagonist candesartan is not effective in reducing portal hypertension in patients with cirrhosis", Digestion, 75, pp.122~123 (2007)[DOI]
  80. De BK, "Portal pressure response to losartan compared with propranolol in patients with cirrhosis", Am J Gastroenterol, 98, pp.1371~1376 (2003)[DOI]
  81. 김재현, "Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension", Clinical and Molecular Hepatology, 20(4), pp.376~383 (2014), 대한간학회
  82. Kim MY, "Beneficial effects of candesartan, an angiotensin-blocking agent, on compensated alcoholic liver fibrosis: a randomized open-label controlled study", Liver Int, 32, pp.977~987 (2012)[DOI]
  83. Abecasis R, "Nadolol plus spironolactone in the prophylaxis of first variceal bleed in nonascitic cirrhotic patients: a preliminary study", Hepatology, 37, pp.359~365 (2003)[DOI]
  84. Sugano S, "Chronic splanchnic hemodynamic effects of spironolactone with unrestricted sodium diet in patients with compensated cirrhosis", Dig Dis Sci, 43, pp.893~897 (1998)[DOI]
  85. Schepke M, "Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension", Gastroenterology, 121, pp.389~395 (2001)[DOI]
  86. Yokohama S, "Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis", World J Gastroenterol, 12, pp.322~326 (2006)[DOI]
  87. Terui Y, "Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C", Hepatology, 36(4), pp.1022~ (2002)[DOI]
  88. Sookoian S, "Effects of six months losartan administration on liver fibrosis in chronic hepatitis C patients: a pilot study", World J Gastroenterol, 11, pp.7560~7563 (2005)[DOI]
  89. Rimola A, "Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation", Transplantation, 78, pp.686~691 (2004)
  90. Corey KE, "The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C", Liver Int, 29, pp.748~753 (2009)[DOI]
  91. Colmenero J, "Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C", Am J Physiol Gastrointest Liver Physiol, 297, pp.G726~G734 (2009)[DOI]
  92. Abu Dayyeh BK, "The effects of angiotensin blocking agents on the progression of liver fibrosis in the HALT-C trial cohort", Dig Dis Sci, 56, pp.564~568 (2011)[DOI]
  93. Goh GB, "Renin-angiotensin system and fibrosis in non-alcoholic fatty liver disease", Liver Int, 35, pp.979~985 (2015)[DOI]
  94. Zhu Q, "Therapeutic effect of renin angiotensin system inhibitors on liver fibrosis", J Renin Angiotensin Aldosterone Syst, 17, pp.1470320316628717~ (2016)
  95. Peiro C, "Endothelial dysfunction through genetic deletion or inhibition of the G protein-coupled receptor Mas: a new target to improve endothelial function", J Hypertens, 25, pp.2421~2425 (2007)[DOI]
  96. 엄영우, "Mesenchymal stem cell therapy for liver fibrosis", The Korean Journal of Internal Medicine, 30(5), pp.580~589 (2015), 대한내과학회[DOI]

관련 논문AI추천

Clinical Implications of the Serum Apelin Level on Portal Hypertension and Prognosis of Liver Cirrhosis권상옥, 김문영, 백순구, Eunhee Choi, Yong Seok Kang, Yoo Li Lim, Yoon Ok Jang, Youn Zoo Cho거트앤리버 소화기연관학회협의회 · Gut and Liver2016 · 제10권 제1호Pharmacological Interventions for Cirrhotic Ascites: From Challenges to Emerging Therapeutic HorizonsChen Yu, Duan Meili, Gao Yuan, Gao Yunyi, Hou Bing, Liu Xin거트앤리버 소화기연관학회협의회 · Gut and Liver2024 · 제18권 제6호Recent Advances in the Pathogenesis and Clinical Evaluation of Portal Hypertension in Chronic Liver DiseaseKawada Norifumi, Kotani Kohei거트앤리버 소화기연관학회협의회 · Gut and Liver2024 · 제18권 제1호Reversal of liver cirrhosis: current evidence and expectations임형준, 정영걸대한내과학회 · The Korean Journal of Internal Medicine2017 · 제32권 제2호Anti-fibrotic treatments for chronic liver diseases: The present and the futureHideki Fujii, Masaru Enomoto, Misako Sato-Matsubara, Naoshi Odagiri, Norifumi Kawada, Tsutomu Matsubara대한간학회 · Clinical and Molecular Hepatology2021 · 제27권 제3호Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension강혜원, 권상옥, 김문영, 김영주, 김재현, 김정민, 김현식, 김현아, 나지훈, 백순구, 조윤주, 차승환대한간학회 · Clinical and Molecular Hepatology2014 · 제20권 제4호

이 간행물의 다른 논문 (27건)

How to tackle congestion in acute heart failureWilfried Mullens, Pieter Martenspp. 462-473Expanding transcatheter aortic valve replacement into uncharted indicationsGuson Kang, Juyong Brian Kimpp. 474-482Fundamental role of dendritic cells in inducing Th2 responsesTae Hoon Kim, Byoungjae Kimpp. 483-489Helicobacter pylori eradication in the treatment of gastric hyperplastic polyps: beyond National Health InsuranceJin Sung Koh, Moon Kyung Joopp. 490-492Wider reference ranges of serum thyroid stimulating hormone in pregnant Korean women: is it time to stop overtreatment?임동준, 조관훈pp. 493-496
원문 보기